Individualized cancer vaccines versus surveillance after adjuvant chemotherapy for surgically resected high-risk stage 2 and stage 3 colorectal cancer: protocol for a randomized trial

被引:3
|
作者
Jones, Robert P. [1 ,2 ]
Lee, Lennard Y. W. [3 ]
Corrie, Pippa G. [4 ]
Danson, Sarah [5 ]
Vimalachandran, Dale [1 ,6 ]
机构
[1] Univ Liverpool, Dept Mol & Clin Canc Med, Inst Syst Mol & Integrat Biol, Liverpool, England
[2] Liverpool Univ Teaching Hosp NHS Fdn Trust, Dept Hepatobiliary Surg, Prescot St, Liverpool L7 8YE, England
[3] Univ Oxford, Dept Oncol, Oxford, England
[4] Cambridge Univ Hosp NHS Fdn Trust, Dept Oncol, Cambridge, England
[5] Univ Sheffield, Dept Oncol, Western Bank, Sheffield, England
[6] Countess Chester NHS Fdn Trust, Dept Colorectal Surg, Chester, England
关键词
D O I
10.1093/bjs/znad332
中图分类号
R61 [外科手术学];
学科分类号
摘要
[No abstract available]
引用
收藏
页码:1883 / 1884
页数:2
相关论文
共 50 条
  • [21] mFOLFIRINOX versus mFOLFOX 6 as adjuvant treatment for high-risk stage III colon cancer - the FROST trial: study protocol for a multicenter, randomized controlled, phase II trial
    Kyung-Ha Lee
    In Jun Yang
    Gi Won Ha
    Jaeim Lee
    Youn Young Park
    Suk Hwan Lee
    Jong Min Lee
    Jung Hoon Bae
    Eun Jung Park
    Hyungjin Kim
    Keun Young Kim
    Sanghyung An
    Ik Yong Kim
    Ji Yeon Kim
    BMC Cancer, 24
  • [22] Adjuvant chemotherapy for high-risk stage II and stage III colon cancer: timing of initiation and optimal duration
    Cruz, Jan Paolo M.
    Pales, Chris George C.
    Kim, Kwang Min
    Kim, Young Wan
    JOURNAL OF BUON, 2018, 23 (03): : 568 - 573
  • [23] mFOLFIRINOX versus mFOLFOX 6 as adjuvant treatment for high-risk stage III colon cancer - the FROST trial: study protocol for a multicenter, randomized controlled, phase II trial
    Lee, Kyung-Ha
    Yang, In Jun
    Ha, Gi Won
    Lee, Jaeim
    Park, Youn Young
    Lee, Suk Hwan
    Lee, Jong Min
    Bae, Jung Hoon
    Park, Eun Jung
    Kim, Hyungjin
    Kim, Keun Young
    An, Sanghyung
    Kim, Ik Yong
    Kim, Ji Yeon
    BMC CANCER, 2024, 24 (01)
  • [24] Surveillance Versus Adjuvant Radiotherapy for Patients With High-Risk Stage I Seminoma
    Mortensen, Mette S.
    Bandak, Mikkel
    Kier, Maria G. G.
    Lauritsen, Jakob
    Agerbk, Mads
    Holm, Niels V.
    von der Maase, Hans
    Daugaard, Gedske
    CANCER, 2017, 123 (07) : 1212 - 1218
  • [25] Risk-Benefit Comparisons Between Shorter and Longer Durations of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer
    McCaw, Zachary R.
    Kim, Dae Hyun
    Wei, Lee-Jen
    JAMA ONCOLOGY, 2020, 6 (08) : 1301 - +
  • [26] Adjuvant chemotherapy versus radiation therapy after radical surgery in high-risk positive node Stage IB/IIA cervical cancer
    Mossa, B.
    Mossa, S.
    Marziani, R.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2010, 31 (05) : 545 - 550
  • [27] Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer
    O'Connell, MJ
    Laurie, JA
    Kahn, M
    Fitzgibbons, RJ
    Erlichman, C
    Shepherd, L
    Moertel, CG
    Kocha, WI
    Pazdur, R
    Wieand, HS
    Rubin, J
    Vukov, AM
    Donohue, JH
    Krook, JE
    Figueredo, A
    JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (01) : 295 - 300
  • [28] Predictive value of pretreatment lymphocyte count in stage II colorectal cancer and in high-risk patients treated with adjuvant chemotherapy
    Liang, Lei
    Zhu, Ji
    Jia, Huixun
    Huang, Liyong
    Li, Dawei
    Li, Qingguo
    Li, Xinxiang
    ONCOTARGET, 2016, 7 (01) : 1014 - 1028
  • [29] ROLE FOR ADJUVANT CHEMOTHERAPY FOR EARLY STAGE COLON CANCER WITH HIGH-RISK FEATURES AFTER SURGICAL RESECTION.
    Wood, E.
    Kalu, R. U.
    Tang, A.
    Reickert, C.
    Nalamati, S.
    Asai, M.
    DISEASES OF THE COLON & RECTUM, 2020, 63 (06) : E435 - E435
  • [30] ADJUVANT CHEMOTHERAPY AFTER ORCHIECTOMY IN HIGH-RISK PATIENTS WITH CLINICAL STAGE-1 NONSEMINOMATOUS TESTICULAR CANCER
    STUDER, UE
    FEY, MF
    CALDERONI, A
    KRAFT, R
    MAZZUCCHELLI, L
    SONNTAG, RW
    EUROPEAN UROLOGY, 1993, 23 (04) : 444 - 449